Abstract
Until recently, the mammalian tachykinins included substance P, neurokinin A and neurokinin B. Following the discovery of the fourth member of this family, hemokinin 1, a diverse group of novel tachykinins and tachykinin gene-related peptides have been identified in mammals. These newly identified members are preferentially expressed in peripheral tissues. Currently, the impact of these new tachykinin peptides on the immune system remains unclear. Some data imply an important role for hemokinin 1 in the generation of lymphocytes. Tachykinins are traditionally viewed as neuropeptides with well-defined functions as neurotransmitters. Many studies however, indicate that they may also be produced by non-neuronal cells, and exert profound influence on inflammatory responses by affecting multiple aspects of immune cell function. It is of great importance to determine whether the new tachykinin peptides have similar effects. A more detailed understanding of the interactions between tachykinins and immune cells may provide the basis for the development of new therapies for inflammatory and immune-mediated diseases.
Keywords: Tachykinin, Substance P, Hemokinin 1, Endokinin, Hematopoiesis, Lymphopoiesis, Immune cells
Current Drug Targets
Title: Tachykinins in the Immune System
Volume: 7 Issue: 8
Author(s): Yu Zhang, Alexandra Berger, Craig D. Milne and Christopher J. Paige
Affiliation:
Keywords: Tachykinin, Substance P, Hemokinin 1, Endokinin, Hematopoiesis, Lymphopoiesis, Immune cells
Abstract: Until recently, the mammalian tachykinins included substance P, neurokinin A and neurokinin B. Following the discovery of the fourth member of this family, hemokinin 1, a diverse group of novel tachykinins and tachykinin gene-related peptides have been identified in mammals. These newly identified members are preferentially expressed in peripheral tissues. Currently, the impact of these new tachykinin peptides on the immune system remains unclear. Some data imply an important role for hemokinin 1 in the generation of lymphocytes. Tachykinins are traditionally viewed as neuropeptides with well-defined functions as neurotransmitters. Many studies however, indicate that they may also be produced by non-neuronal cells, and exert profound influence on inflammatory responses by affecting multiple aspects of immune cell function. It is of great importance to determine whether the new tachykinin peptides have similar effects. A more detailed understanding of the interactions between tachykinins and immune cells may provide the basis for the development of new therapies for inflammatory and immune-mediated diseases.
Export Options
About this article
Cite this article as:
Zhang Yu, Berger Alexandra, Milne D. Craig and Paige J. Christopher, Tachykinins in the Immune System, Current Drug Targets 2006; 7 (8) . https://dx.doi.org/10.2174/138945006778019363
DOI https://dx.doi.org/10.2174/138945006778019363 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
Current Drug Targets Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Use of Fullerenes in Cosmetics
Recent Patents on Biotechnology Rituxan® Immunotherapy and Zevalin® Radioimmunotherapy in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Effect of Lithium on Neurocognitive Functioning
Current Alzheimer Research Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B
Current Medicinal Chemistry Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design